Pazopanib HCl (GW786034 HCl)

Catalog No.S1035

Pazopanib HCl (GW786034 HCl) Chemical Structure

Molecular Weight(MW): 473.98

Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 270 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • IC50 of Pazopanib that block ANDV-induced EC permeability. Endothelial cells were ANDV infected, and 3 days postinfection the permeability of cells in response to VEGF addition was determined in the presence or absence of increasing amounts of kinase inhibitor. (B): VEGFR2-Src inhibitors block ANDV-induced permeability. Endothelial cells were plated on vitronectin-coated Transwell inserts and infected at an MOI of 0.5 in triplicate with ANDV. Three days postinfection, the permeability of ANDV- and mock-infected endothelial cell monolayers was determined at indicated times in the presence or absence of Pazopanib.

    J Virol, 2011, 85(5): 2296-303. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

    MRC5 non-transformed human lung fibroblasts were infected with influenza viruses (100 multiplicity of infection). Two hours after infection the cells were treated with vehicle control; sorafenib tosylate (2mM); pazopanib (2mM); OSU-03012 (2mM); and AR-13 (2mM). Twenty-four hours after infection the cells are treated with live/dead agent where green cells are viable and cells staining yellow or red are considered dead. Cells are examined at 10 magnification in a Hermes wide-field microscope (n¼3 SEM) P<0.05 less than vehicle control level of virus-mediated cell killing.

    J Cell Physiol, 2016, 231(10):2286-302.. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

  • Effect of HDIL-2/TKI on apoptosis of RCC cells. Three RCC cell lines treated with different concentrations of Pazopanib and HDIL-2 and incubated for 48 h. Microscopic images show apoptotic materials 48 h following treatment (arrows show the apoptotic materials in the pazopanib-treated cells).

    Expert Opin Pharmacother 2014 15(11), 1489-99. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
Features A multi-kinase inhibitor.
Targets
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
FGFR [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] Pazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HUVEC NWrUU4RNT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MmHKbY5pcWKrdIOgeIhmKF[HR1[tbY5lfWOnZDDwdo9tcW[ncnH0bY9vKG:oIFjVWmVEew>? MoHmNVg3OjB|OEK=
HUVEC MlP6T4lv[XOnIHHzd4F6 NHPL[3JqdmirYnn0d{BXTUeILXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIG\FS2ZTNTJiaX6gTHVXTUNiY3XscJMhf2m2aDDhckBKSzVyIH;mJQKJxDhibl2= Mo\NNVg3OjB|OEK=
MM NEfO[ZlMcW6jc3WgZZN{[Xl? M1HGcolvcGmkaYTzJHZGT0ZvaX7keYNm\CCyaH;zdIhwenmuYYTpc44hd2ZiZnz0NS=> MmrqNVcyPjR|M{K=
MM.1S M2Xlb2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MYWxNEDPxGdxbVy= NXPVXHJJcW6qaXLpeJMhVU1iQ3XscEBIem:5dHi= NXr6PGEyOTdzNkSzN|I>
MM.1R NYnnWHgzT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NVnZR4hHOTBizsznM41N NWC5col1cW6qaXLpeJMhVU1iQ3XscEBIem:5dHi= MorKNVcyPjR|M{K=
RPMI NXe4R3dYT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= Ml;yNVAh|rypL33M NVPHeJI{cW6qaXLpeJMhVU1iQ3XscEBIem:5dHi= NGHzUYYyPzF4NEOzNi=>
Dox40 M1jtPGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NXj2cmFuOTBizsznM41N MV3pcohq[mm2czDNUUBE\WyuIFfyc5d1cA>? NF:3RXYyPzF4NEOzNi=>
INA-6 MkPGS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M4rWfFExKM7:Zz;tUC=> MkPKbY5pcWKrdIOgUW0hS2WubDDHdo94fGh? NUDjSmtKOTdzNkSzN|I>
OPM2 M4nhc2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1XCfFExKM7:Zz;tUC=> MWDpcohq[mm2czDNUUBE\WyuIFfyc5d1cA>? M171[lE4OTZ2M{Oy
U266 NHPReVFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NGmzTngyOCEQvHevcWw> NYTvdWxzcW6qaXLpeJMhVU1iQ3XscEBIem:5dHi= MoXsNVcyPjR|M{K=
MM.1S MXnjfZRwfG:6aXPpeJkh[XO|YYm= MWmyNEDPxGdxbVy= M17aSolvcGmkaYTzJG1OKEOnbHygV5Vzfmm4YXy= MkW4NVcyPjR|M{K=
MM.1R M4G4XIN6fG:2b4jpZ4l1gSCjc4PhfS=> MXuyNEDPxGdxbVy= NYP0Rm9UcW6qaXLpeJMhVU1iQ3XscEBUfXK4aY\hcC=> MVixO|E3PDN|Mh?=
RPMI M33nVIN6fG:2b4jpZ4l1gSCjc4PhfS=> M2HDelIxKM7:Zz;tUC=> M2fIO4lvcGmkaYTzJG1OKEOnbHygV5Vzfmm4YXy= MoC2NVcyPjR|M{K=
Dox40 NF\UOFdkgXSxdH;4bYNqfHliYYPzZZk> MVyyNEDPxGdxbVy= MXLpcohq[mm2czDNUUBE\WyuIGP1dpZqfmGu MUmxO|E3PDN|Mh?=
INA-6 NWXUU2lH[3m2b4TvfIlkcXS7IHHzd4F6 MYiyNEDPxGdxbVy= M2WxbolvcGmkaYTzJG1OKEOnbHygV5Vzfmm4YXy= NWnrTIVDOTdzNkSzN|I>
OPM2 MlTTZ5l1d3SxeHnjbZR6KGG|c3H5 NV\DVnpuOjBizsznM41N NV3sSGVpcW6qaXLpeJMhVU1iQ3XscEBUfXK4aY\hcC=> NHvLN5cyPzF4NEOzNi=>
U266 NX:5NWRw[3m2b4TvfIlkcXS7IHHzd4F6 M4jNS|IxKM7:Zz;tUC=> MV7pcohq[mm2czDNUUBE\WyuIGP1dpZqfmGu MmnJNVcyPjR|M{K=
MM.1S M2XLcWZ2dmO2aX;uJIF{e2G7 NXTRUYNZe3WycILld5NmeyCYRVfGMWlv\HWlZXSgSY5ld3SqZXzpZYwhS2WubDDQdo9tcW[ncnH0bY9vKGGwZDDNbYdz[XSrb36u M4e2NVE4OTZ2M{Oy
MM.1R MVLGeY5kfGmxbjDhd5NigQ>? MVzzeZBxemW|c3XzJHZGT0ZvSX7keYNm\CCHbnTveIhmdGmjbDDD[YxtKFC{b3zp[oVz[XSrb36gZY5lKE2rZ4LheIlwdi5? NFPL[pUyPzF4NEOzNi=>
Dox40 MkPISpVv[3Srb36gZZN{[Xl? NIP4eXN{fXCycnXzd4V{KF[HR1[tTY5lfWOnZDDFcoRwfGinbHnhcEBE\WyuIGDyc4xq\mW{YYTpc44h[W6mIF3p[5JifGmxbj6= M4HRdlE4OTZ2M{Oy
OPM2 NXrtSVVCTnWwY4Tpc44h[XO|YYm= NWnJRo1Ne3WycILld5NmeyCYRVfGMWlv\HWlZXSgSY5ld3SqZXzpZYwhS2WubDDQdo9tcW[ncnH0bY9vKGGwZDDNbYdz[XSrb36u NETCS3kyPzF4NEOzNi=>
HBMEC MYDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NGT6ZmF,OTBizszN NHjqPZJFVVOR NGTURpBKSzVyPUGg{txO MYKyNVA5OTZ3Nh?=
HBMEC NWfa[JlHTnWwY4Tpc44h[XO|YYm= M{TkXJ4yKM7:TR?= MofzSG1UVw>? M{HWXoFjem:pYYTld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIG\FS2ZTOiC5aYToJIRqe3K3cITpc44hd2ZiZH;3cpN1emWjbTDQUGPPuzF? NGXiUlYzOTB6MU[1Oi=>
HBMEC NH\IenJHfW6ldHnvckBie3OjeR?= MlvyglEh|ryP MoPpSG1UVw>? MXXkbZNzfXC2czD0bIUhWmG|LWLh[k1GWkticHH0bJdigSC2aILveYdpKGSnY4LlZZNm\CCyaH;zdIhwenmuYYTl[EBOTUtzL{KgZY5lKEWUS{GvNi=> Mor3NlExQDF4NU[=
HBMEC NHm4VY9HfW6ldHnvckBie3OjeR?= NYLsTZFDhjJyIN88US=> MlS5SG1UVw>? NGPxdotlcXO{dYD0d{A2OCVib3[geJVj\SCob4LtZZRqd25iYYSgNUDPxE1? M3jpPVIyODhzNkW2
MDA-MB-231 MnS4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NXHQO5VUhjFyIN88US=> M1LLUWROW09? NHzlN4FKSzVyPUWg{txO NVr3fIJMOjFyOEG2OVY>
MDA-MB-231 Mn\NSpVv[3Srb36gZZN{[Xl? NFXM[XkxNjVizszN MUPEUXNQ Mn34bY5pcWKrdIOgeIhmKEWUS{GvNkB{cWewYXzpcocheGG2aIfhfS=> M37HOlIyODhzNkW2
MDA-MB-231 NWPse2xWTnWwY4Tpc44h[XO|YYm= NInXZVg2KM7:TR?= NHjrc3NFVVOR M3fMTIlv\HWlZYOgZUBk\WyuLXP5Z4xmKGG{cnXzeC=> NGf1dHozOTB6MU[1Oi=>
J82 MWLjfZRwfG:6aXPpeJkh[XO|YYm= M37S[J4yOCEQvF2= M2XMdmROW09? NEDI[XhKSzVyPUK0MlU4KM7:TR?= NHLnOI8zOTV{OUmwNC=>
T24 Mk\EZ5l1d3SxeHnjbZR6KGG|c3H5 NISzRnZ,OTBizszN M2DESGROW09? MXvJR|UxRTV{LkS1JO69VQ>? MWOyNVUzQTlyMB?=
HT1376 Mn;kZ5l1d3SxeHnjbZR6KGG|c3H5 NV\SOZdHhjFyIN88US=> MorUSG1UVw>? NXuxN3lMUUN3ME2yPE4zOSEQvF2= MnHKNlE2Ojl7MEC=
RT4 MVzjfZRwfG:6aXPpeJkh[XO|YYm= MmC0glExKM7:TR?= MWrEUXNQ Mnq2TWM2OD13LkG0JO69VQ>? MUGyNVUzQTlyMB?=
CRL1749 MkXpZ5l1d3SxeHnjbZR6KGG|c3H5 NWnrTnBbhjFyIN88US=> MoHDSG1UVw>? MUDJR|UxRTJ{Lk[5JO69VQ>? NVWxR|NKOjF3Mkm5NFA>
HTB9 M1PQXIN6fG:2b4jpZ4l1gSCjc4PhfS=> MWT+NVAh|ryP NV7oPJZ4TE2VTx?= Mn\qTWM2OD1zMT64OEDPxE1? M4Sxc|IyPTJ7OUCw
Sup MV7jfZRwfG:6aXPpeJkh[XO|YYm= NXntem5KhjFyIN88US=> MW\EUXNQ MmHFTWM2OD13Mz6zNkDPxE1? M1zVb|IyPTJ7OUCw
HTB3 Ml3mZ5l1d3SxeHnjbZR6KGG|c3H5 NULqOnpyhjFyIN88US=> MVTEUXNQ M3zoNWlEPTB;MUSuNVYh|ryP MoTPNlE2Ojl7MEC=
CEC MXLGeY5kfGmxbjDhd5NigQ>? MUX+NVAh|rypL33M NFHOV2hFVVOR Mn\x[I94di2{ZXf1cIF1\XNiVlXHSkBt\X[nbIO= M4HlOlIyPjJyOEKy
RPE M{TzS2Z2dmO2aX;uJIF{e2G7 MmTkglExKM7:Zz;tUC=> MnjySG1UVw>? M3:0O4Rwf25vcnXneYxifGW|IG\FS2YhdGW4ZXzz NWfyNmtFOjF4MkC4NlI>
CEC Moi0SpVv[3Srb36gZZN{[Xl? M2XpWp42KM7:Zz;tUC=> NVz0VGRuTE2VTx?= M4rLSYJtd2OtczDlcoRwfGinbHnhcEBk\WyuIH3p[5JifGmxbh?= NEHZPIYzOTZ{MEiyNi=>
5637 MkHlS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NEfyXWRFVVOR MW\JR|UxRTF3LkFihKnPxE1? MnfWNlM5QDd4MEW=
J82 NILGW5BIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MWHEUXNQ MUXJR|UxRTF6LkVihKnPxE1? NWjVUHVnOjN6OEe2NFU>
5637 M1TlO2F2fG:yaHHnfUBie3OjeR?= NHfHOW8zOCEQvF2= MVnEUXNQ MXn0dolo\2W{czD0bIUh[XW2b4DoZYdq[yCycn;j[ZN{ NYrEPGdyOjN6OEe2NFU>
J82 MnmxRZV1d3CqYXf5JIF{e2G7 NEC3ZpIzOCEQvF2= M3nIO2ROW09? NXLnSoY{fHKrZ3fldpMhfGinIHH1eI9xcGGpaXOgdJJw[2W|cx?= MWCyN|g5PzZyNR?=
5637 NUPrdG4yTnWwY4Tpc44h[XO|YYm= NEHR[WozOCEQvF2= NF;hXpBFVVOR M1\3UIlv\HWlZYOgcJl{d3OxbXHsMYRmeGWwZHXueEBv\WO{b4Ppdy=> MkP3NlM5QDd4MEW=
J82 NVfGNoRzTnWwY4Tpc44h[XO|YYm= MXyyNEDPxE1? NUHxTlhrTE2VTx?= MWrpcoR2[2W|IHz5d49{d22jbD3k[ZBmdmSnboSgcoVkem:|aYO= NYrLO3R{OjN6OEe2NFU>
5637 M4T0U2Z2dmO2aX;uJIF{e2G7 MoPmNlAh|ryP M4K4XmROW09? Mo\qbY5lfWOnczDsfZNwe2:vZTDhcJRmemG2aX;uJIFv\CCrbnjpZol1eyCFQjDhZ5Rqfmm2eR?= MV:yN|g5PzZyNR?=
J82 MYrGeY5kfGmxbjDhd5NigQ>? NWHQOZh6OjBizszN NU\5fm5STE2VTx?= MXnpcoR2[2W|IHz5d49{d22nIHHseIVz[XSrb36gZY5lKGmwaHnibZR{KEOEIHHjeIl3cXS7 MnLSNlM5QDd4MEW=
KATO-II M1PF[mdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NVTtbZllPSEQvF2= MVTEUXNQ MWXicI9kc3NicILvcIln\XKjdHnvci=> NUXZNnQ6OjV{NEm1OVc>
OCUM-2M M13ZZ2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MUe1JO69VQ>? MmfTSG1UVw>? Mlq5Zoxw[2u|IIDyc4xq\mW{YYTpc44> MYiyOVI1QTV3Nx?=
SNU-16 MonLS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NVLTSIdUPSEQvF2= NHfzfohFVVOR MXPicI9kc3NicILvcIln\XKjdHnvci=> NUHqeG95OjV{NEm1OVc>
HSC-39 NITDZ|FIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3u4XlUh|ryP NVn1e2FzTE2VTx?= M2HLboJtd2OtczDwdo9tcW[ncnH0bY9v M4fiOFI2OjR7NUW3
KATO-II MnL6Z5l1d3SxeHnjbZR6KGG|c3H5 MUD+NVAh|ryP Mln2SG1UVw>? NVHme5JOUUN3ME2wMlEhfG9iMj6wJO69dW:uL1y= M4n1UVI2OjR7NUW3
OCUM-2M MoXRZ5l1d3SxeHnjbZR6KGG|c3H5 NHjKOVJ,OTBizszN NUHNXY5GTE2VTx?= MYnJR|UxRTBwMTD0c{AzNjBizsztc4wwVA>? MXuyOVI1QTV3Nx?=
SNU-16 MYTjfZRwfG:6aXPpeJkh[XO|YYm= NVntcFFPhjFyIN88US=> M3ToZmROW09? MlvwTWM2OD1yLkGgeI8hOi5yIN88cY9tN0x? NG[4W2wzPTJ2OUW1Oy=>
HSC-39 NX\ocpc3[3m2b4TvfIlkcXS7IHHzd4F6 M2O2RZ4yOCEQvF2= Ml7RSG1UVw>? MWTJR|UxRTBwMTD0c{AzNjBizsztc4wwVA>? MXeyOVI1QTV3Nx?=
NIH 3T3 NHzXU3ZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MnrTglExKM7:TR?= M1uyVmROW09? NF\ZW4xqdmirYnn0d{Bk\WyuIHfyc5d1cCCjbnSgZ49td267IH\vdo1ifGmxbh?= MWKyOVI1QTV3Nx?=
KATO-III NXjzSIRYTnWwY4Tpc44h[XO|YYm= NVvjdZJLOSEQvF2= NVPFcW46TE2VTx?= M2PnOYlv\HWlZYOgZ4VtdC2leXPs[UBienKnc4S= M1;Bc|I2OjR7NUW3
OCUM-2M M3LvUmZ2dmO2aX;uJIF{e2G7 MlTMNUDPxE1? NFXSSHhFVVOR NGjUSGRqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0 M4j5UVI2OjR7NUW3
KATO-III NGfPfo9CeG:ydH;zbZMh[XO|YYm= M37ze|Eh|ryP NYnDVGV4TE2VTx?= M2WyW4lv\HWlZYOgZZBweHSxc3nz MoX6NlUzPDl3NUe=
OCUM-2M M2T4dmFxd3C2b4Ppd{Bie3OjeR?= M2GwU|Eh|ryP NHH1S2FFVVOR NIDCWIdqdmS3Y3XzJIFxd3C2b4Ppdy=> MX6yOVI1QTV3Nx?=
KATO-III NFKzXW5HfW6ldHnvckBie3OjeR?= MVSxJO69VQ>? NIPzR|ZFVVOR NVnYb44zcW6qaXLpeJMhTkeIUkKgdIhwe3Cqb4L5cIF1cW:wIHHu[EBld3ewc4Ty[YFuKHOrZ37hcIlv\yCvb3zlZ5Vt\XN? MmnENlUzPDl3NUe=

... Click to View More Cell Line Experimental Data

In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase enzyme assays:

VEGFR enzyme assays for VEGGR1, VEGFR2, and VEGFR3 are run in homogeneous time-resolved fluorescence (HTRF) format in 384-well microtiter plates using a purified, baculovirus-expressed glutathione-S-transferase (GST) fusion protein encoding the catalytic c-terminus of human VEGFR receptor kinases 1, 2, or 3. Reactions are initiated by the addition of 10 μL of activated VEGFR2 kinase solution [final concentration, 1 nM enzyme in 0.1 M HEPES, pH 7.5, containing 0.1 mg/mL bovine serum albumin (BSA), 300 μM dithiothreitol (DTT)] to 10 μL substrate solution [final concentration, 360 nM peptide, (biotin-aminohexyl-EEEEYFELVAKKKK-NH2), 75 μM ATP, 10 μM MgCl2], and 1 μL of titrated Pazopanib in DMSO. Plates are incubated at room temperature for 60 min, and then the reaction is quenched by the addition of 20 μL of 100 mM ethylene diamine tetraacetic acid (EDTA). After quenching, 20 μL HTRF reagents (final concentration, 15 nM Streptavidin-linked allophycocyanin, 1 nM Europium-labeled antiphosphotyrosine antibody diluted in 0.1 mg/mL BSA, 0.1 M HEPES, pH 7.5) is added and the plates incubated for a minimum of 10 min. The fluorescence at 665 nM is measured with a Wallac Victor plate reader using a time delay of 50 μs.
Cell Research:

[1]

+ Expand
  • Cell lines: HUVEC cells
  • Concentrations: 0-10 μM
  • Incubation Time: 1 hour
  • Method:

    Phosphorylation of VEGFR2 is assessed in HUVEC stimulated with VEGF. HUVEC are plated in type-I collagen-coated 10 cm plates in Clonetics EGM-MV medium at 1.0-1.5 × 106 cells/plate. After 24 hours, the confluent cells are serum starved overnight by replacing the growth medium with Clonetics EBM medium containing 0.1% BSA, 500 μg/mL hydrocortisone. Cells are treated with Pazopanib at various concentrations for 1 hour, followed by addition of 10 ng/mL VEGF or vehicle for 10 min. Cells are solubilized in lysis buffer. VEGFR2 is immunoprecipitated using antiflk-1 antibody and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blotting and detection with antiflk-1 or with antiphosphotyrosine (anti-P-tyr-biotin) antibody. The VEGFR2 phosphorylation level is quantified by densitometry and normalized to the total VEGFR2 level.


    (Only for Reference)
Animal Research:

[2]

+ Expand
  • Animal Models: Immunodeficient mice bearing SYO-1 cells
  • Formulation: --
  • Dosages: 0 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 17 mg/mL (35.86 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 473.98
Formula

C21H23N7O2S.HCl

CAS No. 635702-64-6
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02300545 Recruiting Sarcoma, Soft Tissue|Soft Tissue Sarcoma Washington University School of Medicine April 8, 2015 Phase 2
NCT00674024 Completed Neoplasms|Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 7, 2008 Phase 1
NCT01716416 Recruiting Squamous Cell Carcinoma of the Head and Neck Washington University School of Medicine May 31, 2013 Phase 1
NCT01462630 Recruiting Adult Angiosarcoma|Recurrent Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma Fox Chase Cancer Center|National Cancer Institute (NCI) November 3, 2011 Phase 2
NCT01468922 Completed Sarcoma|Stomach Neoplasms|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 24, 2011 Phase 1
NCT02342600 Not yet recruiting Gastrointestinal Stromal Tumors Sarcoma Alliance for Research through Collaboration|Novartis January 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) supplier | purchase Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) cost | Pazopanib HCl (GW786034 HCl) manufacturer | order Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID